The NCCN® Clinical Practice Guidelines now include ANKTIVA® plus... BCG for patients with BCG-unresponsive NMIBC with papillary-only disease. This update reflects continued progress in expanding treatment considerations for patients facing limited options following BCG therapy. Learn more:show more

We are pleased to announce positive topline event-free survival... results from our Phase 3 study in patients with BCG-naïve, high-risk non-muscle invasive #BladderCancer (NMIBC). Learn more:show more

Today, the Saudi Food and Drug Authority (SFDA) granted... accelerated approval of ANKTIVA® for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more:show more

ImmunityBio reported that median overall survival has not yet... been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA® + CAR-NK-based regimen. As recent American Cancer Society data shows that brain cancer is now the third leading cause of cancer-related death among adults ages 20–49, these findings underscore the urgency of continued innovation in this disease. Read more:show more

We’ve reported ~700% year-over-year revenue growth, expanded ANKTIVA® authorizations... in 33 countries, and continued progress in lung cancer. With additional label expansion plans and global commercialization efforts underway, we remain focused on broadening patient access worldwide. Read more:show more

🚨 FDA APPROVED! Arrowhead’s therapy to lower triglycerides in... adults with Familial Chylomicronemia Syndrome (FCS) offers new hope for patients & families facing this #RareDisease. A major step forward in RNAi innovation. #FCS #FDAApprovalshow more

We’ve announced clinical trial clearances from both the FDA... and Health Canada for our investigational encapsulated cell therapy for the potential treatment of type 1 diabetes. Learn more:show more

This Labour Government is upgrading the NHS app to... give patients more choice over treatment and help cut waiting lists, for good.show more

Israeli warplanes bombed the Turkish-Palestinian Friendship Hospital in Gaza,... which was functioning as the only place for the treatment of cancer patients in the regionshow more

SKMCH&RC FUND METER UPDATE We’ve come this far with... your support & provided free cancer treatment to 75% of our patients this year. Every rupee counts! For home collection of donations, call 080011555 To donate from anywhere in the world 👉 #SKMCHshow more

Phase 1 Data on DVX201: study results demonstrate the... safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease. ICYMI, read more: $COEPshow more

85% to 90% of patients with blastic plasmacytoid dendritic... cell neoplasm (#BPDCN), a rare #bloodcancer, present with skin lesions. #Dermatologists: learn about the signs and symptoms of the disease so you are prepared to spot this uncommon hematologic malignancy.show more

The partnership between #DolceGabbana and Baci® Perugina® continues to... spread the love with the limited edition #BaciAmoreEPassione. #DGBaci: a taste of pure joy to proclaim your love this Valentine's day. Discover more at #BaciPerugina #MadeInItalyshow more

Treat the whole patient with confidence. We’ll help you... create treatment plans for patients with complex comorbidities. Free access to the Comorbidities Manager for all NHS staff and learners, funded by @NHS_HealthEdEng NHS Knowledge for Healthcare #NHSBMJBPshow more

White patients looking for appointments with these doctors 😆

This past month, TRON continued expanding ecosystem access through... integrations with platforms like @OKX. More connectivity, more access, and more ways for users to interact with #TRON globally. 🌐show more

Pfizer’s treatment for #hemophilia A & B received U.S.... FDA approval for two new patient populations, meeting a significant medical need and offering the first subcutaneous non-factor therapy for children ages 6-11 years old with hemophilia B with inhibitors. Learn more:show more

Decision-making got you in tears? Unga-worry. You don’t have... to choose with the #SoulSquareMeal Get four Hotwings®, a piece of chicken and a Licken Loaf® for only R50 #WhyChooseshow more

A video shows engineered heart muscle made up of... allogeneic induced pluripotent stem-cell–derived cardiomyocytes and stromal cells for cardiac remuscularization in patients with heart failure. Read the full BioVAT-HF study results to learn more:show more